Made in Russia

All regions
ENG
Top stories

Rostec's coronavirus drug KOVID-Globulin passed clinical trials

Rostec's coronavirus drug KOVID-Globulin passed clinical trials

The Ministry of Health of the Russian Federation has issued a registration certificate based on the results of research to the development of the Natsimbio holding company (belongs to Rostec) - the drug KOVID-globulin. This was reported by the state corporation.

The drug is based on the blood plasma of people who have already had COVID-19 and contains antibodies to the coronavirus. Its use helps the body to fight the infection and avoid severe disease.

The press service said the results of a double-blind placebo-controlled comparative study showed that seven out of ten patients who took the drug in combination therapy had a reduced risk of the disease progressing to a more severe form. COVID globulin was most effective when used in the early stages of the disease.

In 70% of cases, treatment prevented the development of complications, such as cytokine storm, renal failure, thromboembolic complications, the development of acute respiratory distress syndrome, increased degree of lung damage and worsened clinical symptomatology.

"The world's first drug of specific anti-covalent immunoglobulin has successfully passed the final two phases of clinical trials, proving its safety and effectiveness," said Sergey Chemezov, general director of the state corporation.

The development, he said, will significantly expand the capabilities of medics in Russia in the fight against coronavirus. "Now they have both possible forms of immunization against coronavirus in their arsenal: active - a vaccine and passive - immunoglobulin," he added.

The principle of action of the drug is based on the property of antibodies to neutralize the current circulating strains of coronavirus. Antibodies bind to the protein on the surface of the virus and do not allow it to penetrate into cells, thereby blocking its spread in the body.

General Director of Natsimbio Andrei Zagorski explained that only donor plasma with high antibody titers is used for production. The drug is characterized by a high degree of purification and viral safety, and a higher concentration of antibodies compared to the original raw material.

Made in Russia // Made in Russia

Author: Ksenia Gustova

0